Drug facts

Does tirzepatide cause hair loss?

Reviewed August 2026

Quick answer

Hair loss is a listed adverse reaction on the approved label. In the two pivotal obesity trials it was reported by 5%, 4% and 5% of participants at 5 mg, 10 mg and 15 mg, against 1% on placebo. The label states these reactions were associated with weight reduction, and reports them far more often in female than in male participants.

What the label reports1

Hair loss appears in the label’s table of adverse reactions occurring in at least 2% of treated participants and more often than on placebo, pooled from the two placebo-controlled weight-reduction trials. It sits alongside the reactions reported in 5% or more of participants, which are overwhelmingly gastrointestinal.

Hair loss reported in the pooled weight-reduction trials, by treatment group
Placebo (N=958)1%
5 mg (N=630)5%
10 mg (N=948)4%
15 mg (N=941)5%

The rate does not climb with the dose. It is 5% at the lowest maintenance dose, 4% at the middle one and 5% at the highest. Whatever is happening, the label’s own numbers do not describe a dose-response.

It was reported overwhelmingly by women1

The label breaks the figure down by sex, and the split is the largest single fact on this page. In the pooled trials, hair loss was reported by 7.1% of female and 0.5% of male participants taking tirzepatide, against 1.3% of female and 0% of male participants on placebo.

The label also records how many people stopped treatment because of it: no tirzepatide-treated participant discontinued because of hair loss, and one placebo-treated participant did. That is not a claim that the reaction is trivial. It is a description of how the trials ended, and it is the only thing the label says about severity.

The label ties it to the weight loss, not to the molecule1

The label’s wording is specific: hair loss adverse reactions in treated participants “were associated with weight reduction.” Associated, not caused — and associated with the weight change rather than with the drug directly.

That framing matches a long-standing observation in dermatology. A 2021 review of telogen effluvium, the common form of diffuse non-scarring hair shedding, describes it as usually precipitated by physiological stress such as childbirth or sudden weight loss, and states plainly that the mechanism by which physiological stress influences the human hair cycle is unknown.

Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium — a review of the science and current obstacles. J Dermatol Sci. 2021 Mar. PMID 33541773.

What follows from that is a gap, not an answer: no trial has tested whether tirzepatide affects hair independently of the weight a person loses on it. The trials were designed to measure weight and, later, sleep apnea. Hair was recorded as a reported adverse event, not as an endpoint with a scalp exam behind it.

What the published literature adds, and what it does not2

The published literature on this question is thin, and it says so about itself. A 2024 review in the International Journal of Dermatology concluded that clinical evidence linking GLP-1 agonists to hair loss “remains sparse,” after noting that the theories run in both directions — some proposing disrupted hair growth cycles, others proposing benefit through improved insulin sensitivity.

A systematic review published in September 2025 searched three databases and found five relevant studies in total. It described the findings as conflicting, with some reporting improvement and regrowth and others reporting hair loss as an adverse dermatologic event, and recommended further research to clarify the relationship.

A retrospective cohort study on GLP-1 receptor agonist medications and hair loss was published in the Journal of the American Academy of Dermatology in May 2025. Its abstract is not available through the E-utilities interface we use to verify citations, so we are not summarizing its results here. We would rather name a study we could not read than paraphrase one we did not.

  1. Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024 Sep. PMID 38741261.
  2. Alsuwailem OA, Alanazi R, Almutairi HM, et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025 Sep 16. PMID 41111833.
  3. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025 May. PMID 39863171.

What a compounded vial changes1

On the label — Mounjaro / Zepbound

The 1% placebo comparison exists because there was a placebo group. Every figure above comes from randomized trials of the approved product, at known doses, with the reaction recorded by investigators against a protocol.

In a compounded vial

Not established.

Nothing in the trial data is evidence about a compounded preparation, and nothing in it is evidence against one either. It is reasonable to expect the drug to behave like the drug. What is not established is anything arising from concentration or from how a specific preparation was made — which is the distinction the comparison of compounded tirzepatide and Zepbound works through in full.

Where to take this3

To a prescriber, and if the shedding is significant, to a dermatologist. Hair loss has many causes that have nothing to do with any medication, and a page reporting a trial percentage cannot tell you which one you have. The same is true of the other two reactions people most often connect to weight loss on this drug — feeling tired and losing muscle along with fat.

Sources

  1. FDA prescribing information for ZEPBOUND (tirzepatide), section 6.1, revision 4/2026 DailyMed
  2. PubMed records retrieved through the NCBI E-utilities esummary and efetch endpoints PubMed
  3. Compounded Tirzepatide editorial policy and medical disclaimer — this section states our own position and makes no claim from the label Read it